Enanta Pharmaceuticals Inc (ENTA)

[floblu14]

Might the following new patent be valid for inclusion in the PFIZER suit?

COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS
File Date: .................... 2018-09-28.
Pub Date: .....................2024-03-20

Excerpts:

Background of the Invention:
RSV is the leading cause of acute lower respiratory tract infections (ALRI) and affects patients of all ages. The symptoms in adults are usually not severe and are typically analogous to a mild cold. However, in infants and toddlers the virus can cause lower respiratory tract infections including bronchiolitis or pneumonia with many of them requiring hospitalization. Nearly all children have been infected by age 3. There are known high-risk groups that infection with RSV is more likely to progress into the ALRI. Premature infants and/or infants suffering from lung or cardiac disease are at the highest risk to develop ALRI. Additional high-risk groups include the elderly, adults with chronic heart and/or lung disease, stem cell transplant patients and the immunosuppressed.

DETAILED DESCRIPTION OF THE INVENTION:
The compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compounds of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The compounds may also be administered as suppositories.

Read more:
https://www.patentguru.com/EP3687543B1



.